Article Per Year (5 Year)
p-Index From 2020 - 2025
1.066
P-Index
This Author published in this journals
All Journal Narra J
Fahriani, Marhami
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 6 Documents
Search

 1 
Disruption of childhood vaccination during the COVID-19 pandemic in Indonesia Fahriani, Marhami; Anwar, Samsul; Yufika, Amanda; Bakhtiar, Bakhtiar; Wardani, Elly; Winardi, Wira; Akel, Kaitlyn B.; Wagner, Abram L.; Harapan, Harapan
Narra J Vol. 1 No. 1 (2021): April 2021
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narraj.v1i1.7

Abstract

The aim of this study was to assess the magnitude of childhood vaccination disruption and to determine the predictors of delaying childhood vaccinations during the coronavirus disease 2019 (COVID-19) pandemic among Indonesian parents. We conducted a nationwide, online, cross-sectional study. A set of questionnaires assessed the disruption of childhood vaccinations and possible explanatory variables, including demographic characteristics, current underlying disease, exposure to and confidence in COVID-19 information, perceived risk, attitude and practice on vaccination, and COVID-19 prevention practice. A multivariable linear regression was used to characterize the relationship between explanatory variables and delayed childhood vaccination. We included 1137 respondents for analysis, of which 52.6% were males and 58.4% participants aged between 31 and 50-years old. Disruption of childhood vaccination service in local health facilities was reported in 42.2% (480/1137) of respondents and 13.3% (193/1137) of respondents explained that their children could not be vaccinated because a healthcare facility temporary stopped the vaccination service. Of all respondents, 312 (27.4%) delayed vaccinating their children for a compulsory vaccination shot. Factors associated with higher odds of delaying compulsory vaccinations for children were employment and chronic disease status, flu vaccination status in the past year, and prior COVID-19 infection. In conclusion, there was a significant disruption of childhood vaccination practices in Indonesia during the COVID-19 pandemic. This is not only due to healthcare closures but also due to parents’ practice - delaying the compulsory childhood vaccination for their children. We urge the government to strengthen strategies to ensure childhood vaccination services are available to all children in the country during a pandemic.
Persistence of long COVID symptoms in COVID-19 survivors worldwide and its potential pathogenesis - A systematic review and meta-analysis Fahriani, Marhami; Ilmawan, Muhammad; Fajar, Jonny K.; Maliga, Helnida A.; Frediansyah, Andri; Masyeni, Sri; Yusuf, Hanifah; Nainu, Firzan; Rosiello, Francesco; Sirinam, Salin; Keam, Synat; Ophinni, Youdiil
Narra J Vol. 1 No. 2 (2021): August 2021
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narraj.v1i2.36

Abstract

The study sought to determine the prevalence of persistent long COVID symptoms such as anxiety, depression, dizziness, chest pain, sleep difficulty, palpitations, weight loss, and hair loss among coronavirus disease 2019 (COVID-19) survivors worldwide and to discuss the potential pathogeneses. Potential studies were searched in three databases (PubMed, Scopus, and Web of Science) as of January 30, 2021. Data on study characteristics, patient characteristics during the follow-up, the number of patients with persistent long COVID symptoms and total COVID-19 survivors were collected according to PRISMA guidelines. To assess the quality of studies, the Newcastle-Ottawa scale was used. The estimated prevalence of each long COVID symptom and the association between COVID-19 severity and the occurrence of prolonged symptoms was assessed, if appropriate. The global prevalence of prolonged anxiety was 15.76% (95%CI: 6.36%, 25.15%). Chest pain persisted in 10.36% (239/3,224) of COVID-19 patients (95%CI: 4.92%, 15.80%). Prolonged depression was found in 24 of 548 COVID-19 survivors with an estimated prevalence of 4.32% (95%CI: 2.62%, 6.03%) and dizziness was presented in 4.83% (118/2,219, 95%CI: 1.50%, 8.16%) after recovery. Hair loss was complained by 527 of 2,251 recovered patients (cumulative prevalence of 24.76%, 95%CI: 19.60%, 29.91%), while weight loss was identified in 37 cases among 452 COVID-19 survivors (8.19%, 95%CI: 5.66%, 10.71%). Prolonged palpitation was experienced by 19.38% (211/1,926) survivors with 95%CI: 2.40%, 41.16%. Sleep difficulty was found in 541 of 2,622 COVID-19 survivors (17.87%, 95%CI: 7.55%, 28.20%). The association between COVID-19 severity and the occurrence of persistent long COVID symptoms was not analyzed due to the lack of data. In conclusion, persistent psychological symptoms are frequently reported among COVID-19 survivors. Follow-up studies with a longer duration and larger population are warranted to assess the extent of prolonged symptoms and the quality of life of COVID-19 survivors. Despite various potential pathogeneses that have been hypothesized, a definitive mechanism is yet to be addressed.
Global prevalence of persistent neuromuscular symptoms and the possible pathomechanisms in COVID-19 recovered individuals: A systematic review and meta-analysis Fajar, Jhonny K.; Ilmawan, Muhammad; Mamada, Sukamto; Mutiawati, Endang; Husnah, Milda; Yusuf, Hanifah; Nainu, Firzan; Sirinam, Salin; Keam, Synat; Ophinni, Youdiil; Rosiello, Francesco; Fahriani, Marhami; Rosa, Sandro GV.
Narra J Vol. 1 No. 3 (2021): December 2021
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v1i3.48

Abstract

This study was conducted to determine the prevalence of prolonged neuromuscular symptoms, including fatigue, anosmia, headache, myalgia, and joint pain in COVID-19 survivors hospitalized with mild, moderate, or severe infections worldwide. The search was conducted up to January 30th, 2021 using three databases (PubMed, Scopus, and Web of Science) to identify potentially eligible studies. Data on study characteristics, follow-up characteristics, and severity of COVID-19 during hospitalization were collected in accordance with PRISMA guidelines. The Newcastle-Ottawa scale was used to assess the quality of relevant articles. The estimated prevalence of specific prolonged neuromuscular symptoms and the association between COVID-19 severity and occurrence of prolonged neuromuscular symptoms was analyzed wherever appropriate. Database search yielded 4,050 articles and 22 articles were included for meta-analysis. The estimated prevalence of prolonged fatigue was recorded in 21.2% (95%CI: 11.9%–34.8%) of 3,730 COVID-19 survivors. Persistent anosmia was recorded in 239 of 2,600 COVID-19 survivors (9.7%, 95%CI: 6.1%–15.2%). In 84 out of 2,412 COVID-19 survivors (8.9%, 95%CI: 3.2%–22.6%), prolonged headache was observed. A total of 53 out of 1,125 COVID-19 patients (5.6%, 95%CI: 2.1%–14.2%) complained of persistent myalgia even after being discharged from the hospital. The prevalence of prolonged joint pain was in 15.4% (95%CI: 8.2%–27.2%) of subjects. Due to data scarcity on COVID-19 severity and prolonged neuromuscular symptoms, association analysis could not be conducted. Widespread concern regarding long-term impacts of COVID-19 was raised after several studies reported prolonged symptoms in COVID-19 survivors. Numerous theories have been proposed to address this concern; however, as the research on this pandemic is still ongoing, no explanation is definitive yet. Therefore, follow-up studies in COVID-19 survivors after recovery from COVID-19 are warranted to determine the pathogenesis of prolonged symptoms. PROSPERO registration: CRD42021242332.
Global acceptance and hesitancy of COVID-19 vaccination: A narrative review Hassan , Wardah; Kazmi, Syeda K.; Tahir, Muhammad J.; Ullah , Irfan; Royan, Hibban Ar; Fahriani, Marhami; Nainu, Firzan; Rosa, Sandro GV.
Narra J Vol. 1 No. 3 (2021): December 2021
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v1i3.57

Abstract

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major global health threat to human civilization and has disrupted many aspects of the community around the globe. Vaccination is one of the prominent measures to control the COVID-19 pandemic. More than 120 vaccines have entered human clinical trials and at least 8 vaccines have been fully approved. However, the success of the COVID-19 vaccination programs depends on how the community accepts the vaccines. Despite COVID-19 vaccination having been initiated for a while now, more than 50% of the global population have not been vaccinated. In some low- and middle-income countries (LMICs), the vaccine coverage is less than 20%. Since the decision to accept the new vaccine is complex, understanding the factors underpinning vaccine acceptance is critical. This review aimed to summarize the COVID-19 vaccine acceptance rate around the globe as well as its associated determinants. Information from this study might be important to formulate effective strategies to increase the COVID-19 vaccine coverage, and to be able to achieve herd immunity.
Willingness-to-pay for COVID-19 vaccine in ten low-middle-income countries in Asia, Africa and South America: A cross-sectional study Sallam, Malik; Anwar, Samsul; Yufika, Amanda; Fahriani, Marhami; Husnah, Milda; Kusuma, Hendrix I.; Raad, Rawan; Khiri, Namareg ME.; Abdalla, Rashed YA.; Adam, Rashed Y.; Ismaeil, Mohajer IH.; Ismail, Asma Y.; Kacem, Wajdi; Teyeb, Zeineb; Aloui , Khaoula; Hafsi , Montacer; Dahman, Nesrine Ben Hadj; Ferjani, Manel; Deeb, Dalia; Emad , Dina; Sami, Farah S.; Abbas, Kirellos Said; Monib, Fatma A.; R , Subramaniam; Panchawagh, Suhrud; Sharun, Khan; Anandu, Sunil; Gachabayov, Mahir; Haque , Md A.; Emran, Talha B.; Wendt, Guilherme W.; Ferreto, Lirane ED.; Castillo-Briones, María F.; Inostroza-Morales, Rocío B.; Lazcano-Díaz, Sebastián A.; Ordóñez-Aburto, José T.; Troncoso-Rojas, Jorge E.; Balogun, Emmanuel O.; Yomi, Akele R.; Durosinmi, Abiodun; Adejumo, Esther N.; Ezigbo, Eyiuche D.; Arab-Zozani, Morteza; Babadi, Elham; Kakemam, Edris; Ullah, Irfan; Malik, Najma I.; Dababseh, Deema; Rosiello, Francesco; Enitan , Seyi S.
Narra J Vol. 2 No. 1 (2022): April 2022
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v2i1.74

Abstract

Vaccine hesitancy is considered as one of the greatest challenges to control the ongoing coronavirus disease 2019 (COVID-19) pandemic. A related challenge is the unwillingness of the general public to pay for vaccination. The objective of this study was to determine willingness-to-pay (WTP) for COVID-19 vaccine among individuals from ten low-middle-income countries (LMICs) in Asia, Africa, and South America. Data were collected using an online questionnaire distributed during February - May 2021 in ten LMICs (Bangladesh, Brazil, Chile, Egypt, India, Iran, Nigeria, Pakistan, Sudan, and Tunisia). The major response variable of in this study was WTP for a COVID-19 vaccine. The assessment of COVID-19 vaccine hesitancy was based on items adopted from the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) vaccine hesitancy scale constructs. In this study, 1337 respondents included in the final analysis where the highest number of respondents was from India, while the lowest number was from Egypt. A total of 88.9% (1188/1337) respondents were willing to pay for the COVID-19 vaccination, and 11.1% (149/1337) were not. The average WTP for COVID-19 vaccination was 87.9 US dollars ($), (range: $5-$200). The multivariate model analysis showed that the country, monthly household income, having a history of respiratory disease, the agreement that routine vaccines recommended by health workers are beneficial and having received the flu vaccination within the previous 12 months were strongly associated with the WTP. Based on the country of origin, the highest mean WTP for COVID-19 vaccine was reported in Chile, while the lowest mean WTP for the vaccine was seen among the respondents from Sudan. The availability of free COVID-19 vaccination services appears as a top priority in the LMICs for successful control of the ongoing pandemic. This is particularly important for individuals of a lower socio-economic status. The effects of complacency regarding COVID-19 extends beyond vaccine hesitancy to involve less willingness to pay for COVID-19 vaccine and a lower value of WTP for the vaccine.
Cytotoxic activity of ethyl acetate extract of Chromolaena odorata on MCF7 and T47D breast cancer cells Yusuf, Hanifah; Novia, Hijra; Fahriani, Marhami
Narra J Vol. 3 No. 3 (2023): December 2023
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v3i3.326

Abstract

One of the most cancers in women that can be fatal is breast cancer. Radiation therapy, chemotherapy, or a combination of the two are often used to treat cancer, and these treatments tend to modify the immune system and weaken defences. Using natural compounds from plants has become a research interest to prevent cancer cell development. The aim of this study was to determine the anticancer activities of ethyl acetate extract of Chromolaena odorata (EACO) against breast cancer cells (MCF-7 and T47D). The viability of the cells was determined by the MTT colorimetry assays. The apoptosis test was performed by using flow cytometry. The IC50 value for MCF-7 cells was 218.78 μg/mL and 307.61 μg/mL for T47D. The extract acted selectively against breast cancer cells, with selectivity indexes against MCF-7 and T47D were 12.77 and 9.08, respectively. The viable cells of T47D cells were decreased from 85±36.5% (24 hours) to 54±34% (48 hours) after treatment with IC50 of EACO. Significant decrease of the MCF-7's viable cells were observed between 48 and 72 hours after treatment with IC50 (68.5±17.7% to 51.01±12.1%, respectively). Apoptosis assay showed that T47D and MCF-7 cells were mainly in the necrosis stage (83.35±0.49% and 95.15±1.76%, respectively). This study suggested that ethyl acetate extract of C. odorata is promising to be developed as an anticancer agent.
Co-Authors Abbas, Kirellos Said Abdalla, Rashed YA. Adam, Rashed Y. Adejumo, Esther N. Akel, Kaitlyn B. Aloui , Khaoula Anandu, Sunil Andri Frediansyah, Andri Arab-Zozani, Morteza Babadi, Elham Bakhtiar Bakhtiar Balogun, Emmanuel O. Castillo-Briones, María F. Dababseh, Deema Dahman, Nesrine Ben Hadj Deeb, Dalia Durosinmi, Abiodun Emad , Dina Emran, Talha B. ENDANG MUTIAWATI, ENDANG Enitan , Seyi S. Ezigbo, Eyiuche D. Fajar, Jhonny K. Ferjani, Manel Ferreto, Lirane ED. Firzan Nainu Gachabayov, Mahir Hafsi , Montacer Hanifah Yusuf Haque , Md A. Harapan Harapan Hassan , Wardah Husnah, Milda Ilmawan, Muhammad Inostroza-Morales, Rocío B. Ismaeil, Mohajer IH. Ismail, Asma Y. Jonny K. Fajar Kacem, Wajdi Kakemam, Edris Kazmi, Syeda K. Keam, Synat Khiri, Namareg ME. Kusuma, Hendrix I. Lazcano-Díaz, Sebastián A. Maliga, Helnida A. Malik, Najma I. Mamada, Sukamto Masyeni, Sri Monib, Fatma A. Novia, Hijra Ophinni, Youdiil Ordóñez-Aburto, José T. Panchawagh, Suhrud R , Subramaniam Raad, Rawan Rosa, Sandro GV. Rosiello, Francesco Royan, Hibban Ar Sallam, Malik Sami, Farah S. Samsul Anwar Sharun, Khan Sirinam, Salin Tahir, Muhammad J. Teyeb, Zeineb Troncoso-Rojas, Jorge E. Ullah , Irfan Ullah, Irfan Wagner, Abram L. Wendt, Guilherme W. Wira Winardi, Wira Wiwik Handayani Yomi, Akele R. Yufika, Amanda